Development and validation of the PHM-CPA model to predict in-hospital mortality for cirrhotic patients with acute kidney injury.

IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Digestive and Liver Disease Pub Date : 2024-10-07 DOI:10.1016/j.dld.2024.09.012
Luyan Zheng, Jing Yang, Lingzhu Zhao, Chen Li, Kailu Fang, Shuwen Li, Jie Wu, Min Zheng
{"title":"Development and validation of the PHM-CPA model to predict in-hospital mortality for cirrhotic patients with acute kidney injury.","authors":"Luyan Zheng, Jing Yang, Lingzhu Zhao, Chen Li, Kailu Fang, Shuwen Li, Jie Wu, Min Zheng","doi":"10.1016/j.dld.2024.09.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The presence of acute kidney injury (AKI) significantly increases in-hospital mortality risk for cirrhotic patients. Early prognosis prediction for these patients is crucial. We aimed to develop and validate a machine learning model for in-hospital mortality prediction for cirrhotic patients with AKI.</p><p><strong>Methods: </strong>Data from cirrhotic patients with AKI hospitalized at the First Affiliated Hospital of Zhejiang University between January 1, 2013, and December 31, 2020 were used to train and validate an extreme Gradient Boosting model to predict in-hospital mortality risk. The Boruta algorithm was used for variable selection. The optimal model was selected and named as PHM-CPA (Prediction of in-Hospital Mortality for Cirrhotic Patients with AKI). The PHM-CPA model was then externally validated in patients from eICU Collaborative Research Database (eICU-CRD) and Medical Information Mart for Intensive Care III dataset (MIMIC). The predictive performance of PHM-CPA model was compared with that of logistic regression (LR) model and 25 previously reported models.</p><p><strong>Results: </strong>A total of 519 cirrhotic patients with AKI were enrolled in model training cohort, of whom 118 (23%) died during hospitalization. Fifteen variables from common laboratory tests were selected to develop the PHM-CPA model. The PHM-CPA model achieved an AUROC of 0.816 (95% CI, 0.763-0.861) in the internal validation cohort and 0.787 (95% CI, 0.745-0.830) in the external validation cohort. The PHM-CPA model consistently outperformed the LR model and 25 previously reported models.</p><p><strong>Conclusion: </strong>We developed and validated the PHM-CPA model, comprising readily available clinical variables, which demonstrated superior performance and calibration in predicting in-hospital mortality for cirrhotic patients with AKI.</p>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.dld.2024.09.012","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The presence of acute kidney injury (AKI) significantly increases in-hospital mortality risk for cirrhotic patients. Early prognosis prediction for these patients is crucial. We aimed to develop and validate a machine learning model for in-hospital mortality prediction for cirrhotic patients with AKI.

Methods: Data from cirrhotic patients with AKI hospitalized at the First Affiliated Hospital of Zhejiang University between January 1, 2013, and December 31, 2020 were used to train and validate an extreme Gradient Boosting model to predict in-hospital mortality risk. The Boruta algorithm was used for variable selection. The optimal model was selected and named as PHM-CPA (Prediction of in-Hospital Mortality for Cirrhotic Patients with AKI). The PHM-CPA model was then externally validated in patients from eICU Collaborative Research Database (eICU-CRD) and Medical Information Mart for Intensive Care III dataset (MIMIC). The predictive performance of PHM-CPA model was compared with that of logistic regression (LR) model and 25 previously reported models.

Results: A total of 519 cirrhotic patients with AKI were enrolled in model training cohort, of whom 118 (23%) died during hospitalization. Fifteen variables from common laboratory tests were selected to develop the PHM-CPA model. The PHM-CPA model achieved an AUROC of 0.816 (95% CI, 0.763-0.861) in the internal validation cohort and 0.787 (95% CI, 0.745-0.830) in the external validation cohort. The PHM-CPA model consistently outperformed the LR model and 25 previously reported models.

Conclusion: We developed and validated the PHM-CPA model, comprising readily available clinical variables, which demonstrated superior performance and calibration in predicting in-hospital mortality for cirrhotic patients with AKI.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开发并验证用于预测急性肾损伤肝硬化患者院内死亡率的 PHM-CPA 模型。
背景:急性肾损伤(AKI)的出现大大增加了肝硬化患者的院内死亡风险。对这些患者进行早期预后预测至关重要。我们旨在开发并验证一种机器学习模型,用于预测 AKI 肝硬化患者的院内死亡率:我们使用浙江大学附属第一医院 2013 年 1 月 1 日至 2020 年 12 月 31 日期间住院的 AKI 肝硬化患者的数据,训练并验证了预测院内死亡风险的极端梯度提升模型。变量选择采用 Boruta 算法。选出的最优模型被命名为 PHM-CPA(肝硬化 AKI 患者院内死亡率预测)。随后,PHM-CPA 模型在来自 eICU 合作研究数据库(eICU-CRD)和重症监护医学信息市场 III 数据集(MIMIC)的患者中进行了外部验证。PHM-CPA模型的预测性能与逻辑回归(LR)模型和之前报道的25个模型进行了比较:共有 519 名肝硬化 AKI 患者加入模型训练队列,其中 118 人(23%)在住院期间死亡。PHM-CPA模型选取了常见实验室检测中的15个变量。PHM-CPA 模型在内部验证队列中的 AUROC 为 0.816(95% CI,0.763-0.861),在外部验证队列中的 AUROC 为 0.787(95% CI,0.745-0.830)。PHM-CPA模型的表现一直优于LR模型和之前报道的25种模型:我们开发并验证了 PHM-CPA 模型,该模型由现成的临床变量组成,在预测 AKI 肝硬化患者的院内死亡率方面表现出卓越的性能和校准性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Digestive and Liver Disease
Digestive and Liver Disease 医学-胃肠肝病学
CiteScore
6.10
自引率
2.20%
发文量
632
审稿时长
19 days
期刊介绍: Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.
期刊最新文献
Small bowel metastasis from pulmonary pleomorphic carcinoma. Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial. Dexamethasone improves clinical and biological tolerance of transcatheter arterial chemoembolization for hepatocellular carcinoma. Enhanced bowel prep quality with 1L-PEG vs 2L-PEG and picosulphate: Real-world retrospective study. Exploring the role of fatty acid esters of hydroxy fatty acids in metabolic dysfunction-associated steatotic liver disease in morbidly obese women.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1